Clinical Manual for Management of the HIV-Infected ... - myCME.com

Patient Education
♦
♦
♦
♦
♦
♦
♦
♦
All patients with TB-positive sputum or
bronchoscopy specimens can infect others with
TB. All close contacts, especially children, should
be screened for TB as soon as possible and given
medication to prevent (or treat) active disease.
The health department will be notified of each TB
case and will provide the required follow-up care.
Patients must take all medicines exactly as
prescribed. If doses are missed, or if the medication
is stopped and restarted, the TB bacteria can develop
resistance to even the best medications and become
even more dangerous. If patients are having trouble
taking the medication on schedule, they should
contact their health care providers immediately.
If patients become ill, if their skin or eyes turn
yellow, or if their urine darkens to a cola color, they
should see their health care providers immediately.
Patients must keep all follow-up appointments.
Blood tests will be done regularly to be sure the
liver is working well, and patients will be checked
for medication adverse effects. They should show
their health care providers all medications, vitamins,
and supplements that they are taking so that the
providers can check for drug interactions.
Rifampin will make urine, sweat, and tears turn
orange; this is not harmful. It will also stain plastic
contact lens; patients should avoid wearing these if
they are taking rifampin.
Rifampin will cause birth control pills to fail. An
alternate method of contraception should be used
when the patient is under treatment.
Alcohol should be avoided during treatment with
TB drugs to avoid liver damage.
References
♦
♦
♦
♦
♦
♦
♦
♦
♦
Section 6—Disease-Specific Treatment | 6–73
American Thoracic Society, Centers for Disease
Control and Prevention, Infectious Diseases
Society of America. Treatment of Tuberculosis. Am
J Respir Crit Care Med. 2003 Feb 15;167(4):603-
62. Available online at ajrccm.atsjournals.org/cgi/
content/full/167/4/603. Accessed May 19, 2006.
Blumberg HM, Leonard MK, Jasmer RM. Update
on the treatment of tuberculosis and latent tuberculosis
infection. JAMA. 2005 Jun 8;293(22):2776-84.
Centers for Disease Control and Prevention.
Acquired rifamycin resistance in persons with advanced
HIV disease being treated for active tuberculosis with
intermittent rifamycin-based regimens. Morb Mortal
Wkly Rep. 2002 Mar 15;51(10):214-5.
Centers for Disease Control and Prevention.
Updated guidelines for the use of rifabutin or rifampin
for the treatment and prevention of tuberculosis among
HIV-infected patients taking protease inhibitors or
nonnucleoside reverse transcriptase inhibitors. Morb
Mortal Wkly Rep. 2000 Mar 10;49(9):185-9.
Frieden T, ed. Toman’s Tuberculosis: Case Detection,
Treatment and Monitoring: Questions and Answers,
2nd ed. Geneva: World Health Organization; 2004.
Accessed February 7, 2006.
Harries A, Maher D, Graham S. TB/HIV: A
Clinical Manual, 2nd ed. Geneva: World Health
Organization; 2004. Accessed February 7, 2006.
Iseman MD. Treatment of multidrug-resistant tuberculosis.
N Engl J Med. 1993 Sep 9;329(11):784-91.
Iseman MD. A Clinician's Guide to Tuberculosis.
Philadelphia: Lippincott Williams & Wilkins; 2000.
Reider H.L. Interventions for Tuberculosis Control
and Elimination. 2002. International Union Against
Tuberculosis and Lung Disease. Accessed February
7, 2006.